|
1
|
Fuchs B, Spinner RJ and Rock MG: Malignant
peripheral nerve sheath tumors: An update. J Surg Orthop Adv.
14:168–174. 2005.PubMed/NCBI
|
|
2
|
Widemann BC: Current status of sporadic
and neurofibromatosis type 1-associated malignant peripheral nerve
sheath tumors. Curr Oncol Rep. 11:322–328. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stucky CCH, Johnson KN, Gray RJ, Pockaj
BA, Ocal IT, Rose PS and Wasif N: Malignant peripheral nerve sheath
tumors (MPNST): The Mayo Clinic experience. Ann Surg Oncol.
19:878–885. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Goertz O, Langer S, Uthoff D, Ring A,
Stricker I, Tannapfel A and Steinau HU: Diagnosis, treatment and
survival of 65 patients with malignant peripheral nerve sheath
tumors. Anticancer Res. 34:777–783. 2014.PubMed/NCBI
|
|
5
|
Yaga US, Shivakumar R, Kumar MA and
Sathyaprakash: Malignant peripheral nerve sheath tumor: A rarity.
Indian J Dent. 6:53–56. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Riad S, Biau D, Holt GE, Werier J,
Turcotte RE, Ferguson PC, Griffin AM, Dickie CI, Chung PW, Catton
CN, et al: The clinical and functional outcome for patients with
radiation-induced soft tissue sarcoma. Cancer. 118:2682–2692. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kolarov V, Stanić J, Eri Z, Zvezdin B,
Kojičić M and Hromis S: Intrathoracic malignant peripheral nerve
sheath tumor with poor outcome: A case report. Bosn J Basic Med
Sci. 10:328–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maane LA, Al Bouzidi A, Damou M and
Ismaili N: Primary intrapulmonary malignant peripheral nerve sheath
tumor: A rare case. Cancer Treat Res Commun. 25:1002432020.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grzywa-Celińska A, Szmygin-Milanowska K,
Emeryk-Maksymiuk J, Walczyna M, Palonka M and Siwiec J: Malignant
peripheral nerve sheath tumor in a patient without
neurofibromatosis 1 (NF1): A rare case of primary lung location. J
Educ Health Sport. 8:11–17. 2018.
|
|
10
|
Inci I, Soltermann A, Schneiter D and
Weder W: Pulmonary malignant peripheral nerve sheath tumour. Eur J
Cardiothorac Surg. 46:331–332. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
La Mantia E, Franco R, Cantile M, Rocco R,
De Chiara A, Martucci N and Rocco G: Primary intrapulmonary
malignant peripheral nerve sheath tumor mimicking lung cancer. J
Thorac Dis. 5:E155–E157. 2013.PubMed/NCBI
|
|
12
|
Desdiani D, Darifah S and Azali C: Giant
intrapulmonary malignant peripheral nerve sheath tumour. Respirol
Case Rep. 8:e005672020. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bradford D and Kim A: Current treatment
options for malignant peripheral nerve sheath tumors. Curr Treat
Options Oncol. 16:3282015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Committee of Consensus of
Immunohistochemistry Test on Technology, . Consensus of
immunohistochemistry test on technology. Zhonghua Bing Li Xue Za
Zhi. 48:87–91. 2019.(In Chinese). PubMed/NCBI
|
|
15
|
Farid M, Demicco EG, Garcia R, Ahn L,
Merola PR, Cioffi A and Maki RG: Malignant peripheral nerve sheath
tumors. Oncologist. 19:193–201. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sharma S, Shah JS and Bali H: Malignant
peripheral nerve sheath tumor: A rare malignancy. J Oral Maxillofac
Pathol. 24 (Suppl 1):S86–S90. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thway K and Fisher C: Malignant peripheral
nerve sheath tumor: Pathology and genetics. Ann Diagn Pathol.
18:109–116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pekmezci M, Reuss DE, Hirbe AC, Dahiya S,
Gutmann DH, von Deimling A, Horvai AE and Perry A: Morphologic and
immunohistochemical features of malignant peripheral nerve sheath
tumors and cellular schwannomas. Mod Pathol. 28:187–200. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rodriguez FJ, Folpe AL, Giannini C and
Perry A: Pathology of peripheral nerve sheath tumors: Diagnostic
overview and update on selected diagnostic problems. Acta
Neuropathol. 123:295–319. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Olsen SH, Thomas DG and Lucas DR: Cluster
analysis of immunohistochemical profiles in synovial sarcoma,
malignant peripheral nerve sheath tumor, and Ewing sarcoma. Mod
Pathol. 19:659–668. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schaefer IM and Fletcher CDM: Recent
advances in the diagnosis of soft tissue tumours. Pathology.
50:37–48. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Prieto-Granada CN, Wiesner T, Messina JL,
Jungbluth AA, Chi P and Antonescu CR: Loss of H3K27me3 expression
is a highly sensitive marker for sporadic and radiation-induced
MPNST. Am J Surg Pathol. 40:479–489. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schaefer IM, Fletcher CD and Hornick JL:
Loss of H3K27 trimethylation distinguishes malignant peripheral
nerve sheath tumors from histologic mimics. Mod Pathol. 29:4–13.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cleven AH, Al Sannaa GA, Briaire-De Bruijn
I, Ingram DR, van de Rijn M, Rubin BP, de Vries MW, Watson KL,
Torres KE, Wang WL, et al: Loss of H3K27 tri-methylation is a
diagnostic marker for malignant peripheral nerve sheath tumors and
an indicator for an inferior survival. Mod Pathol. 29:582–590.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Grobmyer SR, Reith JD, Shahlaee A, Bush CH
and Hochwald SN: Malignant peripheral nerve sheath tumor: Molecular
pathogenesis and current management considerations. J Surg Oncol.
97:340–349. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gupta G, Mammis A and Maniker A: Malignant
peripheral nerve sheath tumors. Neurosurg Clin N Am. 19533–543.
(v)2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kroep JR, Ouali M, Gelderblom H, Le Cesne
A, Dekker TJA, Van Glabbeke M, Hogendoorn PCW and Hohenberger P:
First-line chemotherapy for malignant peripheral nerve sheath tumor
(MPNST) versus other histological soft tissue sarcoma subtypes and
as a prognostic factor for MPNST: An EORTC soft tissue and bone
sarcoma group study. Ann Oncol. 22:207–214. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chamoto K, Al-Habsi M and Honjo T: Role of
PD-1 in immunity and diseases. Curr Top Microbiol Immunol.
410:75–97. 2017.PubMed/NCBI
|
|
29
|
Dong ZY, Wu SP, Liao RQ, Huang SM and Wu
YL: Potential biomarker for checkpoint blockade immunotherapy and
treatment strategy. Tumor Biol. 37:4251–4261. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang S, Liechty B, Patel S, Weber JS,
Hollmann TJ, Snuderl M and Karajannis MA: Programmed death ligand 1
expression and tumor infiltrating lymphocytes in neurofibromatosis
type 1 and 2 associated tumors. J Neurooncol. 138:183–190. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Farschtschi S, Kluwe L, Park SJ, Oh SJ,
Mah N, Mautner VF and Kurtz A: Upregulated immuno-modulator PD-L1
in malignant peripheral nerve sheath tumors provides a potential
biomarker and a therapeutic target. Cancer Immunol Immunother.
69:1307–1313. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu J, Li H, Wei C, Li Q and Wang Z: PD-L1
expression and tumor infiltrating lymphocytes in neurofibromatosis
type 1-related benign tumors and malignant peripheral nerve sheath
tumors: An implication for immune checkpoint inhibition therapy.
Chin J Plast Reconstr Surg. 3:63–75. 2021. View Article : Google Scholar
|
|
33
|
Larson K, Russ A, Arif-Tiwari H, Mahadevan
D, Elliott A, Bhattacharyya A and Babiker H: Pembrolizumab achieves
a complete response in an NF-1 mutated, PD-L1 positive malignant
peripheral nerve sheath tumor: A case report and review of the
benchmarks. J Immunother. 45:222–226. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Payandeh M, Sadeghi M and Sadeghi E:
Complete response to pembrolizumab in a patient with malignant
peripheral nerve sheath tumor: The first case reported. J App Pharm
Sci. 7:182–184. 2017.
|
|
35
|
Davis LE, Nicholls LA, Babiker HM, Liau J
and Mahadevan D: PD-1 inhibition achieves a complete metabolic
response in a patient with malignant peripheral nerve sheath tumor.
Cancer Immunol Res. 7:1396–1400. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Özdemir BC, Bohanes P, Bisig B, Missiaglia
E, Tsantoulis P, Coukos G, Montemurro M, Homicsko K and Michielin
O: Deep response to anti-PD-1 therapy of metastatic
neurofibromatosis type 1-associated malignant peripheral nerve
sheath tumor with CD274/PD-L1 amplification. JCO Precis Oncol.
3:1–6. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mckean M, Tolcher AW, Reeves JA,
Chmielowsk B, Shaheen MF, Beck JT, Orloff MM, Somaiah N, Van Tine
BA, Drabick JJ, et al: Newly updated activity results of
alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus
pembrolizumab: Phase 2 study in adults and children with various
solid tumors. J Clin Oncol. 40 (16 Suppl):S9517–2022. View Article : Google Scholar
|
|
38
|
González-Muñoz T, Kim A, Ratner N and
Peinado H: The need for new treatments targeting MPNST: The
potential of strategies combining MEK inhibitors with
antiangiogenic agents. Clin Cancer Res. 28:3185–3195. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Paudel SN, Hutzen B and Cripe TP: The
quest for effective immunotherapies against malignant peripheral
nerve sheath tumors: Is there hope? Mol Ther Oncolytics.
30:227–237. 2023. View Article : Google Scholar : PubMed/NCBI
|
